Latin American Cooperative Oncology Group
Clinical trials sponsored by Latin American Cooperative Oncology Group, explained in plain language.
-
Chemo-Free hope for HER2+ breast cancer patients in new trial
Disease control OngoingThis study tests whether certain women with early-stage HER2-positive breast cancer can be treated with a targeted drug combination (PHESGO™) without chemotherapy. Researchers use specific markers to select patients whose tumors are highly dependent on the HER2 pathway. The goal …
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Bipolar hormone therapy shows promise in stubborn prostate cancer
Disease control OngoingThis phase 2 trial is testing a combination of two hormone-based drugs—darolutamide and high-dose testosterone—in 51 men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The approach, called extreme bipolar androgen…
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug cocktail shows promise for EGFR lung cancer
Disease control OngoingThis Phase 2 trial tests a combination of three drugs—amivantamab, lazertinib, and pemetrexed—as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. The study includes 54 participants across Latin America. Researchers want to see if this comb…
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Prostate cancer study pulled before it began
Knowledge-focused TerminatedThis study was designed to see if a person's race or ethnicity changes how well a combination of drugs (niraparib, abiraterone acetate, and prednisone) works for a specific type of advanced prostate cancer. It planned to compare Black or Hispanic participants with White or Native…
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC